Abstract
Impulse control disorders (ICD) are frequent side effects of dopamine replacement therapy (DRT) used in Parkinson’s disease (PD) with devastating consequences on the patients and caregivers. ICD are behavioural addictions including compulsive gambling, shopping, sexual behaviour, and binge eating that are mainly associated with dopamine D2/D3 agonists. Their management is a real clinical challenge due to the lack of therapeutic alternative. Clinical studies have identified demographic and clinical risk factors for ICD such as younger age at disease onset, male gender, prior history of depression or substance abuse, REM sleep behaviour disorders and higher rate of dyskinesia. PD patients with ICD may also have a specific pattern of dopaminergic denervation in the ventral striatum. Specific evaluation tools have now been designed to better evaluate the severity and impact of ICD in PD. Patients with ICD display altered processing of reward and loss, and decisional bias associated with altered activity in cortical and subcortical areas such as the orbitofrontal cortex, amygdala, insula, anterior cingular cortex, and ventral striatum. Preclinical studies have demonstrated that D2/D3 agonists induce impairments in behavioural processes likely relevant to ICD such as risk-taking behaviour, preference for uncertainty, perseverative responding and sustained drive to engage in gambling-like behaviour. Whether interactions between dopamine denervation and DRT significantly contribute to the pathogenesis of ICD remains poorly understood so far, although features unique to PD have been identified in patients with ICD. Large-scale longitudinal studies are needed to better identify subjects with increased risk to develop ICD and develop therapeutic options.
Similar content being viewed by others
References
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Washington, DC
Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol Dis 6:461–474. https://doi.org/10.1006/nbdi.1999.0259
Antonelli F et al (2014) Dopamine-agonists and impulsivity in Parkinson’s disease: impulsive choices vs. impulsive actions. Hum Brain Mapp 35:2499–2506. https://doi.org/10.1002/hbm.22344
Antonini A et al (2011) Impulsivity and compulsivity in drug-naïve patients with Parkinson’s disease. Mov Disord Off J Mov Disord Soc 26:464–468. https://doi.org/10.1002/mds.23501
Aracil-Bolaños I, Strafella AP (2016) Molecular imaging and neural networks in impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 22(Suppl 1):S101–S105. https://doi.org/10.1016/j.parkreldis.2015.08.003
Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F (2006) Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord 21:2068–2072. https://doi.org/10.1002/mds.21072
Baig F et al (2017) Personality and addictive behaviours in early Parkinson’s disease and REM sleep behaviour disorder. Parkinsonism Relat Disord 37:72–78. https://doi.org/10.1016/j.parkreldis.2017.01.017
Balarajah S, Cavanna AE (2013) The pathophysiology of impulse control disorders in Parkinson disease. Behav Neurol 26:237–244. https://doi.org/10.3233/BEN-2012-120266
Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case–control study. Clin Endocrinol 80:863–868. https://doi.org/10.1111/cen.12375
Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ (2013) Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord 28:327–333. https://doi.org/10.1002/mds.25291
Bastide MF et al (2015) Pathophysiology of l-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol 132:96–168. https://doi.org/10.1016/j.pneurobio.2015.07.002
Baunez C, Robbins TW (1999) Effects of dopamine depletion of the dorsal striatum and further interaction with subthalamic nucleus lesions in an attentional task in the rat. Neuroscience 92:1343–1356
Bentivoglio AR, Baldonero E, Ricciardi L, De Nigris F, Daniele A (2013) Neuropsychological features of patients with Parkinson’s disease and impulse control disorders. Neurol Sci 34:1207–1213. https://doi.org/10.1007/s10072-012-1224-5
Biundo R et al (2015) Patterns of cortical thickness associated with impulse control disorders in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 30:688–695. https://doi.org/10.1002/mds.26154
Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, Comings DE (1996) The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 89:396–400
Bodi N et al (2009) Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson’s patients. Brain 132:2385–2395. https://doi.org/10.1093/brain/awp094
Bonfanti AB, Gatto EM (2010) Kleptomania, an unusual impulsive control disorder in Parkinson’s disease? Parkinsonism Relat Disord 16:358–359. https://doi.org/10.1016/j.parkreldis.2010.02.004
Bonnaire C, Bungener C, Varescon I (2013) Alexithymia and gambling: a risk factor for all gamblers? J Gambl Stud 29:83–96. https://doi.org/10.1007/s10899-012-9297-x
Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE (2009) Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc 84:310–316. https://doi.org/10.1016/S0025-6196(11)60538-7
Bourdenx M et al (2015) Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol Commun 3:46. https://doi.org/10.1186/s40478-015-0222-2
Campbell JC, Jeyamohan SB, De La Cruz P, Chen N, Shin D, Pilitsis JG (2014) Place conditioning to apomorphine in rat models of Parkinson’s disease: differences by dose and side-effect expression. Behav Brain Res 275:114–119. https://doi.org/10.1016/j.bbr.2014.09.002
Canesi M, Rusconi ML, Moroni F, Ranghetti A, Cereda E, Pezzoli G (2016) Creative thinking professional artists, and Parkinson’s disease. J Parkinsons Dis 6:239–246. https://doi.org/10.3233/JPD-150681
Cenci MA, Tranberg A, Andersson M, Hilbertson A (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-dopa treatment. Neuroscience 94:515–527
Cenci MA, Francardo V, O’Sullivan SS, Lindgren HS (2015) Rodent models of impulsive–compulsive behaviors in Parkinson’s disease: how far have we reached? Neurobiol Dis 82:561–573. https://doi.org/10.1016/j.nbd.2015.08.026
Cerasa A et al (2013) Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement. Parkinsonism Relat Disord 19:123–125. https://doi.org/10.1016/j.parkreldis.2012.06.003
Chernoloz O, El Mansari M, Blier P (2009) Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 34:651–661. https://doi.org/10.1038/npp.2008.114
Chernoloz O, El Mansari M, Blier P (2012) Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J Psychiatry Neurosci 37:113–121. https://doi.org/10.1503/jpn.110038
Christenson GA et al (1994) Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 55:5–11
Cilia R, van Eimeren T (2011) Impulse control disorders in Parkinson’s disease: seeking a roadmap toward a better understanding. Brain Struct Funct 216:289–299. https://doi.org/10.1007/s00429-011-0314-0
Cilia R et al (2010) Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis 39:98–104. https://doi.org/10.1016/j.nbd.2010.03.013
Cilia R et al (2011) Pathological gambling in patients with Parkinson’s disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord 26:225–233. https://doi.org/10.1002/mds.23480
Cocker PJ, Tremblay M, Kaur S, Winstanley CA (2017) Chronic administration of the dopamine D2/3 agonist ropinirole invigorates performance of a rodent slot machine task, potentially indicative of less distractible or compulsive-like gambling behaviour. Psychopharmacology 234:137–153. https://doi.org/10.1007/s00213-016-4447-y
Cormier F, Muellner J, Corvol JC (2013) Genetics of impulse control disorders in Parkinson’s disease. J Neural Transm (Vienna) 120:665–671. https://doi.org/10.1007/s00702-012-0934-4
Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH (2010) Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case–control study. Sleep 33:81–87
Dardou D, Reyrolle L, Chassain C, Durif F (2017) Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area. Behav Brain Res 332:327–336. https://doi.org/10.1016/j.bbr.2017.06.016
Decressac M, Mattsson B, Bjorklund A (2012a) Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson’s disease. Exp Neurol 235:306–315. https://doi.org/10.1016/j.expneurol.2012.02.012
Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A (2012b) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis 45:939–953. https://doi.org/10.1016/j.nbd.2011.12.013
Djamshidian A et al (2010) Risk and learning in impulsive and nonimpulsive patients with Parkinson’s disease. Mov Disord 25:2203–2210. https://doi.org/10.1002/mds.23247
Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE (2005) Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62:1377–1381. https://doi.org/10.1001/archneur.62.9.noc50009
Doucet JP et al (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8:365–381
Driver-Dunckley ED et al (2007) Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30:249–255. https://doi.org/10.1097/wnf.0b013e31804c780e
Engeln M, Ahmed SH, Vouillac C, Tison F, Bezard E, Fernagut PO (2013a) Reinforcing properties of Pramipexole in normal and parkinsonian rats. Neurobiol Dis 49:79–86. https://doi.org/10.1016/j.nbd.2012.08.005
Engeln M, Fasano S, Ahmed SH, Cador M, Baekelandt V, Bezard E, Fernagut PO (2013b) Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann Neurol 74:140–144. https://doi.org/10.1002/ana.23881
Engeln M, Ansquer S, Dugast E, Bezard E, Belin D, Fernagut PO (2016a) Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2016.05.013
Engeln M et al (2016b) Selective inactivation of striatal FosB/DeltaFosB-expressing neurons alleviates l-DOPA-induced dyskinesia. Biol Psychiatry 79:354–361. https://doi.org/10.1016/j.biopsych.2014.07.007
Evans AH, Katzenschlager R, Paviour D, O’Sullivan JD, Appel S, Lawrence AD, Lees AJ (2004) Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397–405. https://doi.org/10.1002/mds.20045
Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ (2005) Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65:1570–1574. https://doi.org/10.1212/01.wnl.0000184487.72289.f0
Fantini ML et al (2017) Sleep and REM Sleep Behavior disorder in Parkinson’s disease with impulse control disorder. J Neurol Neurosurg Psychiatry
Fantini ML et al (2015) Increased risk of impulse control symptoms in Parkinson’s disease with REM sleep behaviour disorder. J Neurol Neurosurg Psychiatry 86:174–179. https://doi.org/10.1136/jnnp-2014-307904
Faust-Socher A, Kenett YN, Cohen OS, Hassin-Baer S, Inzelberg R (2014) Enhanced creative thinking under dopaminergic therapy in Parkinson disease. Ann Neurol 75:935–942. https://doi.org/10.1002/ana.24181
Garcia-Ruiz PJ et al (2014) Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:840–844. https://doi.org/10.1136/jnnp-2013-306787
Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C (2007) New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 21:501–506. https://doi.org/10.1177/0269881106073109
Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423–428
Goerlich-Dobre KS, Probst C, Winter L, Witt K, Deuschl G, Möller B, van Eimeren T (2014) Alexithymia-an independent risk factor for impulsive–compulsive disorders in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 29:214–220. https://doi.org/10.1002/mds.25679
Gombash SE et al (2013) Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One 8:e81426. https://doi.org/10.1371/journal.pone.0081426
Grall-Bronnec M et al (2017) Dopamine agonists and impulse control disorders: a complex association. Drug Saf. https://doi.org/10.1007/s40264-017-0590-6
Grant JE, Levine L, Kim D, Potenza MN (2005) Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 162:2184–2188
Holtz NA, Tedford SE, Persons AL, Grasso SA, Napier TC (2016) Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 70:77–84. https://doi.org/10.1016/j.pnpbp.2016.05.004
Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, Antonini A (2008) The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord 23:411–415. https://doi.org/10.1002/mds.21872
Johnson PS, Madden GJ, Brewer AT, Pinkston JW, Fowler SC (2011) Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats. Psychopharmacology 213:11–18. https://doi.org/10.1007/s00213-010-2006-5
Johnson PS, Madden GJ, Stein JS (2012) Effects of acute pramipexole on male rats’ preference for gambling-like rewards II. Exp Clin Psychopharmacol 20:167–172. https://doi.org/10.1037/a0027117
Keitz M, Koerts J, Kortekaas R, Renken R, de Jong BM, Leenders KL (2008) Prefrontal cortex and striatal activation by feedback in Parkinson’s disease. Brain Res 1236:225–233. https://doi.org/10.1016/j.brainres.2008.07.110
Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE (2005) Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism Relat Disord 11:381–386. https://doi.org/10.1016/j.parkreldis.2005.06.005
Koffarnus MN, Newman AH, Grundt P, Rice KC, Woods JH (2011) Effects of selective dopaminergic compounds on a delay-discounting task. Behav Pharmacol 22:300–311. https://doi.org/10.1097/FBP0b013e3283473bcb
Kraemmer J et al (2016) Clinical-genetic model predicts incident impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2015-312848
Lee JY, Lee EK, Park SS, Lim JY, Kim HJ, Kim JS, Jeon BS (2009) Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord 24:1803–1810. https://doi.org/10.1002/mds.22678
Lee JY, Kim JM, Kim JW, Cho J, Lee WY, Kim HJ, Jeon BS (2010) Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 16:202–207. https://doi.org/10.1016/j.parkreldis.2009.12.002
Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A (2012) Carer burden in apathy and impulse control disorders in Parkinson’s disease. Int J Geriatr Psychiatry 27:160–166. https://doi.org/10.1002/gps.2704
Llewellyn DJ (2008) The psychology of risk taking: toward the integration of psychometric and neuropsychological paradigms. Am J Psychol 121:363–376
Loiodice S et al (2017) Pramipexole induced place preference after l-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications. Psychopharmacology 234:15–27. https://doi.org/10.1007/s00213-016-4430-7
Lundblad M, Decressac M, Mattsson B, Bjorklund A (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA 109:3213–3219. https://doi.org/10.1073/pnas.1200575109
Madden GJ, Johnson PS, Brewer AT, Pinkston JW, Fowler SC (2010) Effects of pramipexole on impulsive choice in male wistar rats. Exp Clin Psychopharmacol 18:267–276. https://doi.org/10.1037/a0019244
Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB, Weintraub D (2008) Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord 23:75–80. https://doi.org/10.1002/mds.21770
Marechal E, Denoiseux B, Thys E, Crosiers D, Pickut B, Cras P (2015) Impulse control disorders in Parkinson’s disease: an overview from neurobiology to treatment. J Neurol 262:7–20. https://doi.org/10.1007/s00415-014-7361-4
Marques A, Figorilli M, Pereira B, Derost P, Debilly B, Beudin P, Vidal T, Durif F (2018) Psycho-behavioral profile of Parkinson’s disease patients with RLS: a cross sectional-study. Sleep Med. https://doi.org/10.1016/j.sleep.2018.02.004
McCormick PN, Fletcher PJ, Wilson VS, Browne JD, Nobrega JN, Remington GJ (2015) Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer. Neuropharmacology 89:225–231. https://doi.org/10.1016/j.neuropharm.2014.09.026
Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791–804. https://doi.org/10.1124/jpet.102.039867
O’Sullivan SS, Djamshidian A, Evans AH, Loane CM, Lees AJ, Lawrence AD (2010) Excessive hoarding in Parkinson’s disease. Mov Disord 25:1026–1033. https://doi.org/10.1002/mds.23016
O’Sullivan SS et al (2011) Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive–compulsive behaviours. Brain. https://doi.org/10.1093/brain/awr003
Ouachikh O, Dieb W, Durif F, Hafidi A (2013) Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area. Behav Brain Res 252:24–31. https://doi.org/10.1016/j.bbr.2013.05.042
Ouachikh O, Dieb W, Durif F, Hafidi A (2014) Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats. Behav Brain Res 262:1–7. https://doi.org/10.1016/j.bbr.2013.12.021
Pes R et al (2017) Pramipexole enhances disadvantageous decision-making: lack of relation to changes in phasic dopamine release. Neuropharmacology 114:77–87. https://doi.org/10.1016/j.neuropharm.2016.11.014
Phu AL et al (2014) Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patients. J Clin Neurosci 21:63–66. https://doi.org/10.1016/j.jocn.2013.02.032
Pitchers KK, Frohmader KS, Vialou V, Mouzon E, Nestler EJ, Lehman MN, Coolen LM (2010) DeltaFosB in the nucleus accumbens is critical for reinforcing effects of sexual reward. Genes Brain Behav 9:831–840. https://doi.org/10.1111/j.1601-183X.2010.00621.x
Poletti M, Bonuccelli U (2012a) Impulse control disorders in Parkinson’s disease: the role of personality and cognitive status. J Neurol 259:2269–2277. https://doi.org/10.1007/s00415-012-6506-6
Poletti M, Bonuccelli U (2012b) Personality traits in patients with Parkinson’s disease: assessment and clinical implications. J Neurol 259:1029–1038. https://doi.org/10.1007/s00415-011-6302-8
Politis M et al (2013) Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson’s disease. Brain 136:400–411. https://doi.org/10.1093/brain/aws326
Quiroga-Varela A, Aguilar E, Iglesias E, Obeso JA, Marin C (2017) Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: a new progressive and bilateral rodent model of Parkinson’s disease. Neuroscience 361:144–156. https://doi.org/10.1016/j.neuroscience.2017.08.017
Ray NJ, Strafella AP (2013) Imaging impulse control disorders in Parkinson’s disease and their relationship to addiction. J Neural Transm 120:659–664. https://doi.org/10.1007/s00702-012-0933-5
Ray NJ et al (2012) Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis 48:519–525. https://doi.org/10.1016/j.nbd.2012.06.021
Riddle JL, Rokosik SL, Napier TC (2012) Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson’s disease and controls. Behav Brain Res 233:15–23. https://doi.org/10.1016/j.bbr.2012.04.027
Rieu I et al (2015) International validation of a behavioral scale in Parkinson’s disease without dementia. Mov Disord 30:705–713. https://doi.org/10.1002/mds.26223
Rizos A et al (2016) A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 23:1255–1261. https://doi.org/10.1111/ene.13034
Robison AJ, Nestler EJ (2011) Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 12:623–637. https://doi.org/10.1038/nrn3111
Rokosik SL, Napier TC (2012) Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson’s disease and controls. Neuropsychopharmacology 37:1397–1408. https://doi.org/10.1038/npp.2011.325
Rossi M et al (2010) Decision-making in Parkinson’s disease patients with and without pathological gambling. Eur J Neurol 17:97–102. https://doi.org/10.1111/j.1468-1331.2009.02792.x
Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P (2009) Cognitive dysfunctions and pathological gambling in patients with Parkinson’s disease. Mov Disord Off J Mov Disord Soc 24:899–905. https://doi.org/10.1002/mds.22472
Santangelo G, Trojano L, Barone P, Grossi D, Vitale C (2013) Impulse control disorders and cognitive dysfunctions in patients with Parkinson’s disease. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 34:2045–2046. https://doi.org/10.1007/s10072-013-1355-3
Santangelo G, Piscopo F, Barone P, Vitale C (2017) Personality in Parkinson’s disease: clinical, behavioural and cognitive correlates. J Neurol Sci 374:17–25. https://doi.org/10.1016/j.jns.2017.01.013
Scullin MK et al (2013) Sleep and impulsivity in Parkinson’s disease. Parkinsonism Relat Disord 19:991–994. https://doi.org/10.1016/j.parkreldis.2013.06.018
Singh A, Kandimala G, Dewey RB Jr, O’Suilleabhain P (2007) Risk factors for pathologic gambling and other compulsions among Parkinson’s disease patients taking dopamine agonists. J Clin Neurosci 14:1178–1181. https://doi.org/10.1016/j.jocn.2007.01.009
Siri C et al (2010) Cognitive status of patients with Parkinson’s disease and pathological gambling. J Neurol 257:247–252. https://doi.org/10.1007/s00415-009-5301-5
Siri C et al (2015) Long-term cognitive follow-up of Parkinson’s disease patients with impulse control disorders. Mov Disord Off J Mov Disord Soc 30:696–704. https://doi.org/10.1002/mds.26160
Steeves TD et al (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132:1376–1385. https://doi.org/10.1093/brain/awp054
Tedford SE, Persons AL, Napier TC (2015) Dopaminergic lesions of the dorsolateral striatum in rats increase delay discounting in an impulsive choice task. PloS One 10:e0122063. https://doi.org/10.1371/journal.pone.0122063
Tessitore A et al (2016) Cortical thickness changes in patients with Parkinson’s disease and impulse control disorders. Parkinsonism Relat Disord 24:119–125. https://doi.org/10.1016/j.parkreldis.2015.10.013
Tessitore A et al (2017) Resting-state brain networks in patients with Parkinson’s disease and impulse control disorders. Cortex 94:63–72. https://doi.org/10.1016/j.cortex.2017.06.008
Tremblay M, Silveira MM, Kaur S, Hosking JG, Adams WK, Baunez C, Winstanley CA (2017) Chronic D2/3 agonist ropinirole treatment increases preference for uncertainty in rats regardless of baseline choice patterns. Eur J Neurosci 45:159–166. https://doi.org/10.1111/ejn.13332
Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A (2012) Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord 18:397–399. https://doi.org/10.1016/j.parkreldis.2011.10.019
van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP (2009) Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson’s disease? Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 34:2758–2766. https://doi.org/10.1038/sj.npp.npp2009124
Velazquez-Sanchez C, Ferragud A, Moore CF, Everitt BJ, Sabino V, Cottone P (2014) High trait impulsivity predicts food addiction-like behavior in the rat. Neuropsychopharmacology 39:2463–2472. https://doi.org/10.1038/npp.2014.98
Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22:2221–2228. https://doi.org/10.1002/mds.21696
Vitale C, Santangelo G, Trojano L, Verde F, Rocco M, Grossi D, Barone P (2011) Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson’s disease. Mov Disord 26:830–836. https://doi.org/10.1002/mds.23567
Voon V, Fox SH (2007) Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64:1089–1096. https://doi.org/10.1001/archneur.64.8.1089
Voon V et al (2006) Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66:1750–1752. https://doi.org/10.1212/01.wnl.0000218206.20920.4d
Voon V et al (2010) Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology 207:645–659. https://doi.org/10.1007/s00213-009-1697-y
Voon V, Schoerling A, Wenzel S, Ekanayake V, Reiff J, Trenkwalder C, Sixel-Doring F (2011a) Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 11:117. https://doi.org/10.1186/1471-2377-11-117
Voon V et al (2011b) Impulse control disorders in Parkinson disease: a multicenter case–control study. Ann Neurol 69:986–996. https://doi.org/10.1002/ana.22356
Vriend C et al (2014) Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease. Mov Disord 29:904–911. https://doi.org/10.1002/mds.25886
Weintraub D et al (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63:969–973. https://doi.org/10.1001/archneur.63.7.969
Weintraub D et al (2009) Validation of the questionnaire for impulsive–compulsive disorders in Parkinson’s disease. Mov Disord 24:1461–1467. https://doi.org/10.1002/mds.22571
Weintraub D et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595. https://doi.org/10.1001/archneurol.2010.65
Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A (2012) Questionnaire for impulsive–compulsive disorders in Parkinson’s disease—Rating Scale. Mov Disord 27:242–247. https://doi.org/10.1002/mds.24023
Weintraub D, Papay K, Siderowf A, Parkinson’s Progression Markers I (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case–control study. Neurology 80:176–180. https://doi.org/10.1212/WNL.0b013e31827b915c
Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord 30:121–127. https://doi.org/10.1002/mds.26016
Williams-Gray CH et al (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain J Neurol 132:2958–2969. https://doi.org/10.1093/brain/awp245
Zengin-Toktas Y, Authier N, Denizot H, Chassain C, Hafidi A, Llorca PM, Durif F (2013) Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and l-dopa, in bilateral 6-OHDA-lesioned rat. Neuropharmacology 70:74–82. https://doi.org/10.1016/j.neuropharm.2012.12.011
Zuckerman M, Kuhlman DM (2000) Personality and risk-taking: common biosocial factors. J Pers 68:999–1029
Author information
Authors and Affiliations
Corresponding author
Additional information
Invited review for the special issue “Recent advances in the understanding of dyskinesia and non-motor side effects of l-DOPA”.
Rights and permissions
About this article
Cite this article
Marques, A., Durif, F. & Fernagut, PO. Impulse control disorders in Parkinson’s disease. J Neural Transm 125, 1299–1312 (2018). https://doi.org/10.1007/s00702-018-1870-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-018-1870-8